BioVector® KMCH-1 Human Combined Hepatocellular-Cholangiocarcinoma Cell Line / KMCH-1 人肝细胞-胆管细胞混合癌细胞株

一 产品基本信息与细胞生物学背景

• 细胞名称：KMCH-1（常用别名包括：KMCH1、KMCH_1）。

• 物种来源：人类（Homo sapiens），供体为一名52岁的男性患者。

• 组织源起：源自原发性肝脏部位的恶性肿瘤组织（Primary Liver Tumor），经体外原代分离建立。

• 肿瘤病理学分类（罕见的“混合型”标杆模型）：

  KMCH-1 是全球肝胆肿瘤转化医学研究中极为罕见且珍贵的人原发性混合型肝细胞-胆管细胞癌（Combined Hepatocellular-Cholangiocarcinoma, cHCC-CCA 或 CHC）细胞模型。在病理切片和克隆演变中，该细胞展现出独特的双向分化表型，即同时具备肝细胞癌（HCC）的腺泡/条索状特征和胆管细胞癌（CCA/ChC）的间质促纤维化及腺管样构型。

• 核心表型、异质性与干细胞标记物（质控数据）：

  • 上皮样单层贴壁：形态学上主要表现为经典的多角形上皮样（Epithelial-like）形态，呈密集单层贴壁生长。

  • 双向生物标记物表达谱：KMCH-1 保留了双向肿瘤抗原。它高表达胆管上皮特异性标记物细胞角蛋白7（Cytokeratin 7, K7）、细胞角蛋白19（K19）以及 ABCG2。同时，在特定亚群中保留了产生甲胎蛋白（AFP）的潜能。

  • 干细胞亚群异质性（核心分选特征）：研究证实 KMCH-1 群体内部存在显著的肝上皮干/祖细胞（HSPC）样层级异质性：

    • $\text{EpCAM}^+$（上皮细胞粘附分子阳性）亚群：高表达 K19 mRNA，不表达 AFP，在裸鼠体内接种具有极高的致瘤性，且能同时分化发育出 CCA 样和 HCC 样的混合癌组织。

    • $\text{EpCAM}^-$ 亚群：特异性表达 AFP mRNA，不表达 K19，体内接种倾向于仅形成单纯的 HCC 样肿瘤。

  • 白介素-6（IL-6）自分泌环路：KMCH-1 能够高度组成性分泌 IL-6（Constitutive IL-6 secretion）。其细胞膜表面拥有完整的 IL-6 受体复合物（IL-6R/gp130），在受到炎性因子（如 TNF-$\alpha$ 或 IL-1$\beta$）刺激时会进一步触发爆发式分泌，通过旁分泌/自分泌机制极强地激活下游的 p44/p42 MAPK 和 p38 MAPK 信号通路，维持其恶性增殖。

• 致瘤性与恶性度：在软琼脂中具有克隆形成能力，接种于无毛裸鼠（Nude mice）皮下极易形成高度拟真的异质性异种移植瘤（Xenograft）。

二 核心科研价值与转化医学应用

由于混合型肝癌（cHCC-CCA）临床预后极差且缺乏统一的靶向治疗标准，KMCH-1 具有不可替代的药理学研究价值：

1. 肝胆双特征肿瘤异质性与靶向/免疫联合化疗药物筛选：

   用于评估小分子多靶点酪氨酸激酶抑制剂（TKIs，如索拉非尼、仑伐替尼）或针对免疫检查点（PD-1/PD-L1）的靶向药物，在面对同时含有 HCC 和 CCA 两种抗药因子的混合肿瘤时的联合杀伤效率。

2. IL-6 驱动型炎症转导机制与肿瘤微环境（TME）阻断研究：

   KMCH-1 是研究“炎-癌转化”机制的理想工具。常用于测试 IL-6 中和抗体、JAK/STAT 抑制剂或 MAPK 通路阻断剂（如 PD098059）对切断该癌细胞自分泌促生长环路、诱导细胞凋亡的有效性。

3. 肿瘤干细胞（CSC）分化与定向重塑研究：

   利用其 $\text{EpCAM}^+$ 祖细胞亚群，探索小分子化合物、非编码 RNA 或表观遗传修饰剂能否诱导其发生分化阻断，或者将其逆转为低恶性度的单一分化类型。

三 实验室细胞复苏、高效传代与长期保存标准步骤

1. 专用完全培养基配方与生长环境

• 基础培养基：高质量高糖 DMEM（含 L-谷氨酰胺）或高级 RPMI-1640。

• 完全培养基典型配方：

  • 高糖 DMEM 或 RPMI-1640 基础培养基

  • 加 10% 优质胎牛血清（FBS）。

  • 加 1% 青霉素-链霉素双抗。

  • 可选添加：1% 丙酮酸钠（Sodium Pyruvate）和 1% 非必需氨基酸（NEAA）以维持其复杂的上皮代谢环境。

• 培养物理参数：标准 37 摄氏度，恒温高湿度饱和，含 5% 二氧化碳（$CO_2$） 的无菌常规孵箱。

2. 冷冻细胞的复苏与贴壁接种

1. 提前在无菌安全柜中向 T25 培养瓶内注入 5 mL 预热至 37 ℃ 的完全培养基。

2. 从液氮罐中取出 KMCH-1 冻存管，立刻全量投入 37 ℃ 恒温水浴箱中，快速用力摇晃，在 1 分钟内使其完全融化。

3. 用 75% 酒精喷洒消毒外壁后移入安全柜。

4. 将细胞悬液缓慢滴加至盛有 4 mL 预热完全培养基的 15 mL 离心管中，轻柔混匀。

5. 以 1000 rpm（约 200 g）离心 5 分钟。

6. 抽干含有 DMSO 的上清液，加入 1 - 2 mL 完全培养基轻柔重悬胞泥。

7. 接种至 T25 瓶中，十字摇匀，置于 37 ℃ 孵箱中培养。24 小时后观察细胞贴壁汇合度并彻底更换一次新鲜培养基，去除残余碎屑。

3. 日常贴壁常规传代操作流程

• 传代时机：KMCH-1 呈典型的密集多角形上皮样单层排列。当细胞密度达到 80% - 90% 汇合度 时必须传代。该细胞生长较为旺盛，通常每 3 - 4 天需要传代一次。避免让细胞过度长满（$\gt 95\%$），否则由于高度接触抑制和 IL-6 浓度过载，细胞会开始形成多层重叠生长并发生表型老化。

• 操作传代步骤：

  1. 吸除旧培养基，用无菌 PBS 缓冲液轻轻漂洗细胞表面 1 次以洗净残余血清。

  2. 加入适量 0.25% Trypsin - 0.02% EDTA 消化液（T25 瓶常规加入 1 mL），使其均匀覆盖细胞层，置于 37 ℃ 孵箱中消化。

  3. 倒置显微镜下严格动态观察：由于其上皮粘附特性，通常需要消化 2 - 4 分钟。当观察到绝大部分多角形细胞回缩变圆、胞间缝隙明显增大、轻敲瓶身可见细胞成片松动脱落时，必须立刻倒入 2 倍体积的含血清完全培养基终止消化。

  4. 用移液枪轻柔吹打瓶壁 3 - 4 次，将贴壁细胞彻底打散，调理成均匀的单细胞悬液（注意避免过度用力吹打产生大量气泡，气泡产生的剪切力会损伤癌细胞表面受体）。

  5. 收集悬液，1000 rpm 离心 5 分钟，弃上清。

  6. 加入新鲜完全培养基重悬，按照 1:3 至 1:4 的常规比例传代，接种至新培养瓶中，补足培养基放回孵箱。

4. 模型稳定性与质控防线

1. 防范交叉污染（Cross-contamination Control）：KMCH-1 作为增殖极其活跃的实体瘤细胞，在长期传代中必须严格与大肠癌细胞（如 HCT116）或常规高生长细胞（如 HeLa）隔开操作，每 10 - 15 代应定期进行 STR（短串联重复序列）基因分型鉴定，确保该混合型肝癌的特异性遗传本底未发生改变。

2. 分化状态监控：如果长期维持在高密度状态下传代，可能会导致 $\text{EpCAM}^+$ 祖细胞亚群自发耗竭或完全向 HCC 样单向转化。实验中若发现细胞形态由紧密的多角形逐渐完全变成松散的长条异形，应及时淘汰并复苏低代数种子。

5. 细胞长期保存标准

• 冻存液配方：55% 基础 DMEM/RPMI-1640 培养基 + 35% 优质胎牛血清（FBS）+ 10% 分析级二甲基亚砜（DMSO）；或者使用高保护性的商业化无血清细胞冻存液。

• 冷冻梯度降温规范：

  1. 收集处于对数生长最旺盛期（汇合度约 80%）、未老化的健康 KMCH-1 细胞，离心吸除上清。

  2. 用配制好的冻存液重悬，调整细胞终密度至 每毫升 1.5×10⁶ 至 3×10⁶ 个活细胞。

  3. 分装入无菌冻存管，拧紧后立刻放入标准程序降温盒（Mr. Frosty）。

  4. 将降温盒投入 -80 ℃ 超低温冰箱中慢速梯度降温过夜（确保维持 $-1\text{ }^\circ\text{C/min}$ 的标准降温速率）。

  5. 24 小时内，迅速将冻存管转移并锁死在液氮罐（-196 ℃）中实施长期封存。禁止在 -80 ℃ 冰箱中长期搁置，以确保复苏时异质性干细胞亚群的存活率和双向分化潜能不受破坏。

Part 2 English Section

I Product General Information and Cell Biological Background

• Cell Line Name: KMCH-1 (Alternative nomenclature: KMCH1, KMCH_1).

• Organism Source: Human (Homo sapiens), isolated from a 52-year-old male donor.

• Tissue Extract: Primary malignant tumor tissue biopsied from the liver mass.

• Tumor Pathological Classification (A Rare "Mixed-Type" Benchmark):

  KMCH-1 represents a globally distinct, highly valued cell model for investigating primary human Combined Hepatocellular-Cholangiocarcinoma (cHCC-CCA or CHC).

  In histopathological profiling and clonal selection, this cell line preserves a dual-lineage differentiation phenotype, mimicking tumors that simultaneously present areas of typical Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma (CCA/ChC) embedded within a desmoplastic stroma.

• Core Phenotype, Heterogeneity, and Progenitor Footprint:

  • Epithelial Monolayer Growth: Exhibits a classic polygonal epithelial-like morphology, proliferating as a cohesive, adherent monolayer under standard conditions.

  • Bilineage Biomarker Expression Profile: KMCH-1 constitutively retains hepatobiliary tumor antigens. It strongly expresses cholangiocyte-specific markers Cytokeratin 7 (K7), Cytokeratin 19 (K19), and ABCG2, while maintaining the capacity to synthesize Alpha-Fetoprotein (AFP) within designated subsets.

  • Stem Cell Sub-Population Heterogeneity: Research confirms a clear hepatic stem/progenitor cell (HSPC) hierarchy within KMCH-1 cultures:

    • $\text{EpCAM}^+$ Sub-population: Expresses K19 mRNA but lacks AFP. It displays enhanced tumorigenicity in nude mice, regenerating mixed tumors containing both ChC and HCC-like components.

    • $\text{EpCAM}^-$ Sub-population: Selectively expresses AFP mRNA but lacks K19. Upon inoculation, it produces tumors restricted solely to an HCC-like lineage.

  • Autocrine Interleukin-6 (IL-6) Signaling Loop: KMCH-1 cells exhibit constitutive IL-6 secretion. They express functional IL-6 receptor complexes (IL-6R/gp130) on their plasma membrane. Exposure to inflammatory cytokines (e.g., TNF-$\alpha$ or IL-1$\beta$) drives an autocrine and paracrine cascade, activating downstream p44/p42 MAPK and p38 MAPK pathways to fuel malignant cell division.

• Tumorigenic Potential: Demonstrates high colony-forming efficiency in soft agar and rapidly generates highly representative heterogeneous xenografts when injected subcutaneously into athymic nude mice.

II Strategic Research Value and Translational Applications

Because combined liver cancer (cHCC-CCA) is clinically aggressive and lacks standardized target therapies, KMCH-1 serves as a critical pharmaceutical discovery platform:

1. Screening Targeted and Immune Combination Chemotherapies:

   Used to assess the efficacy of small-molecule multikinase inhibitors (e.g., Sorafenib, Lenvatinib) combined with immune checkpoint inhibitors (anti-PD-1/PD-L1) against mixed tumors that contain multiple drug-resistance factors.

2. Dissecting IL-6 Driven Inflammation Signaling Pathways:

   An optimal tool for studying inflammation-associated tumorigenesis. It is widely applied to test whether IL-6 neutralizing antibodies, JAK/STAT inhibitors, or MAPK pathway blockers (e.g., PD098059) can disrupt the cell's autocrine loop and trigger programmed cell death.

3. Cancer Stem Cell (CSC) Differentiation and Plasticity:

   Utilizing the $\text{EpCAM}^+$ progenitor pool, researchers evaluate whether small molecules, non-coding RNAs, or epigenetic modulators can block self-renewal or force differentiation into a single, less aggressive lineage.

III Laboratory Thawing, Passaging, and Cryopreservation Protocols

1. Basal Media Optimization and Environmental Parameters

• Basal Medium Base: High-quality High-Glucose DMEM (fortified with L-Glutamine) or premium RPMI-1640.

• Complete Growth Matrix Formulation:

  • High-Glucose DMEM or RPMI-1640 basal template

  • Supplemented with 10% premium Fetal Bovine Serum (FBS).

  • Fortified with 1% standard Penicillin-Streptomycin dual antibiotic cocktail.

  • Optional: 1% Sodium Pyruvate and 1% Non-Essential Amino Acids (NEAA) to support its complex epithelial metabolic requirements.

• Physical Processing Constants: Incubate strictly at 37 °C, packed with 5% Carbon Dioxide ($CO_2$) under continuous humified saturation conditions.

2. Cryovial Thawing and Recovery Protocol

1. Pre-warm a sterile T25 culture flask filled with 5 mL of complete growth medium to 37 °C inside the biosafety workstation.

2. Retrieve the KMCH-1 cryovial from liquid nitrogen and submerge it instantly within a 37 °C water bath. Agitate continuously to melt the internal matrix within 60 seconds.

3. Mist the exterior shell with 75% ethanol before transfer into the sterile workstation.

4. Draw up the liquid and transfer it slowly into a 15 mL conical tube containing 4 mL of pre-warmed complete growth medium to dilute the toxic DMSO footprint.

5. Centrifuge the suspension at 1000 rpm (~200 g) for 5 minutes.

6. Aspirate the supernatant completely, and gently resuspend the cell pellet in 1 - 2 mL of fresh complete growth medium.

7. Dispense the suspension into the prepared T25 flask, mix gently in a cross pattern, and incubate at 37 °C. Perform a complete medium change after 24 hours to remove residual cell debris and unattached elements.

3. Routine Adherent Passaging Workflow

• Confluency Assessment Control: Passaging workflows must be initialized when the adherent polygonal epithelial monolayer achieves 80% – 90% confluency. The line proliferates actively, typically requiring passaging every 3 to 4 days. Do not allow cultures to become over-confluent ($\gt 95\%$); dense cultures trigger contact inhibition and excessive IL-6 accumulation, causing multi-layered cell stacking and phenotypic aging.

• Passaging Execution Steps:

  1. Aspirate the spent growth fluid and wash the monolayer once with sterile, calcium/magnesium-free PBS, then discard the wash.

  2. Apply an appropriate layer of 0.25% Trypsin - 0.02% EDTA solution (typically 1 mL for a T25 format) and incubate at 37 °C.

  3. Microscopic Tracking: Monitor continuously under an inverted microscope. Due to strong epithelial adhesion properties, trypsinization typically requires 2 – 4 minutes at 37 °C. The moment the polygonal cells contract, intercellular spaces widen, and sheets loosen upon gentle tapping, add 2 volumes of serum-fortified complete growth medium to halt enzymatic cleavage.

  4. Gently pipette the suspension 3 to 4 times against the flask wall to dissociate clusters into a single-cell suspension. Avoid vigorous pipetting to prevent bubbles, which generate shear forces that can damage cell surface receptors.

  5. Collect the suspension, centrifuge at 1000 rpm for 5 minutes, and discard the supernatant.

  6. Resuspend the pellet in fresh complete growth medium and split the culture using standard ratios of 1:3 to 1:4. Seed into new flasks, top off with complete medium, and return to the incubator.

4. Model Fidelity and Quality Assurance Safeguards

1. Cross-contamination Safeguards: Because KMCH-1 is a highly proliferative tumor line, it must be handled separately from other rapidly growing lines (such as HCT116 or HeLa) to avoid cross-contamination. Perform STR (Short Tandem Repeat) profiling every 10 to 15 passages to verify its unique genetic background.

2. Phenotypic Drift Monitoring: Sustained cultivation at excessive densities can cause the spontaneous loss of the $\text{EpCAM}^+$ progenitor pool, driving a unidirectional shift toward a pure HCC-like phenotype. If the cells lose their tight polygonal shape and become elongated or fibroblastic, discard the batch and re-thaw a fresh low-passage vial.

5. Long-Term Cryopreservation Parameters

• Cryoprotectant Preservation Formula: 55% basal DMEM/RPMI-1640 growth medium + 35% premium Fetal Bovine Serum (FBS) + 10% analytical-grade Dimethyl Osmoxide (DMSO), or a certified high-protection commercial serum-free freezing matrix.

• Controlled Gradient Freezing Protocol:

  1. Harvest highly viable, mid-log phase cultures (approximately 80% confluent), ensuring the cells are non-senescent. Centrifuge and isolate the pellet.

  2. Resuspend the cells in the pre-chilled cryoprotectant matrix, adjusting the target density to between 1.5×10⁶ and 3×10⁶ viable cells per milliliter.

  3. Transfer the solution into sterile cryovials, tightening the caps securely. Place them immediately into a standard controlled-rate cooling container (e.g., Mr. Frosty).

  4. Deposit the container inside a -80 °C ultra-low freezer overnight to execute a steady cooling rate of -1 °C/minute.

  5. Within 24 hours, transfer the vials into liquid nitrogen storage tanks (-196 °C) for long-term preservation. Do not store vials long-term at -80 °C; tight temperature regulation is mandatory to preserve the survival rate and dual-differentiation potential of its sensitive progenitor cell fractions.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址http://www.biovector.net